KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Sells 174,645 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par sold 174,645 shares of the company’s stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $16.95, for a total transaction of $2,960,232.75. Following the completion of the sale, the insider directly owned 5,129,340 shares of the company’s stock, valued at approximately $86,942,313. This trade represents a 3.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Thursday, March 26th, Venrock Healthcare Capital Par sold 39,986 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $18.28, for a total transaction of $730,944.08.

KalVista Pharmaceuticals Trading Up 2.0%

NASDAQ KALV opened at $19.33 on Friday. KalVista Pharmaceuticals, Inc. has a one year low of $9.23 and a one year high of $19.95. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. The company has a market capitalization of $990.08 million, a price-to-earnings ratio of -4.89 and a beta of -0.35. The company’s 50-day simple moving average is $16.04 and its two-hundred day simple moving average is $14.46.

KalVista Pharmaceuticals News Roundup

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Unusual bullish options flow: traders bought 5,072 call options (≈569% above the average of 758), suggesting speculative or hedged bullish positioning that can amplify near-term upside interest in the shares.
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and reiterated a “buy” rating — a large upside vs. the current level that often attracts renewed investor attention and buying. Stifel price target raise
• Positive Sentiment: Needham & Company increased its target to $36 and kept a “buy” rating, reinforcing analyst conviction from multiple firms. Needham target raise
• Positive Sentiment: EKTERLY commercial launch showing strong initial revenue: KalVista reported $49.1M in EKTERLY revenue during an eight-month transition period — a material commercial proof point that supports revenue growth expectations. EKTERLY revenue report
• Positive Sentiment: Stock hit a new 52-week high after analyst upgrades and increased coverage, a technical signal that can attract momentum buyers. 52-week high / analyst upgrade
• Neutral Sentiment: Recent earnings materials (Q1 2025 call summary and transcript) have been published — useful for revisiting guidance and management commentary but the market reaction depends on details and forward guidance. Q1 2025 earnings call summary
• Negative Sentiment: Citizens Jmp trimmed its price target slightly from $29 to $28 (still a “market outperform”), a modest downtick in one analyst’s view that could temper upside expectations if other firms follow. Citizens Jmp target change

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets raised its stake in KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of KalVista Pharmaceuticals during the third quarter valued at about $55,000. Wolverine Asset Management LLC purchased a new position in shares of KalVista Pharmaceuticals in the 3rd quarter valued at approximately $57,000. Truvestments Capital LLC boosted its stake in KalVista Pharmaceuticals by 253.8% in the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after purchasing an additional 3,360 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in KalVista Pharmaceuticals during the 3rd quarter worth approximately $63,000.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on KALV shares. Needham & Company LLC boosted their price objective on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. HC Wainwright upped their price objective on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Citizens Jmp cut their target price on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research note on Thursday. Finally, Stifel Nicolaus increased their price target on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, KalVista Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $32.60.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.